Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy

被引:0
|
作者
Stec, Maria [1 ]
Suleja, Agata [1 ]
Gondko, Daniel [1 ]
Kuczmik, Wiktoria [1 ]
Roman, Jakub [1 ]
Dziadosz, Dominika [2 ]
Szydlo, Krzysztof [2 ]
Mizia-Stec, Katarzyna [2 ]
机构
[1] Med Univ Silesia, Students Res Grp, Dept Cardiol 1, 47 Ziolowa St, PL-40635 Katowice, Poland
[2] Med Univ Silesia, Dept Cardiol 1, European Reference Network Heart Dis ERN GUARD HE, 47 Ziolowa St, PL-40635 Katowice, Poland
关键词
hypertrophic cardiomyopathy; atrial fibrillation; HCM-AF Risk Score; ATRIAL-FIBRILLATION; DIAGNOSIS; PROFILE;
D O I
10.3390/jcm12134484
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, p < 0.001; r = 0.346, p < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (p < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (p < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] New sudden cardiac death risk score in hypertrophic cardiomyopathy clinical application in a referral clinic and correlation with clinical, genetic and imaging data
    Gomes, A. C.
    Cruz, I.
    Rocha Lopes, L.
    Caldeira, D.
    Stuart, B.
    Morgado, G.
    Almeida, S.
    Miranda, R.
    Brandao, L.
    Pereira, H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 178 - 178
  • [32] Clinical Outcomes of Cardiac Device Implantation in Patients With Underlying Hypertrophic Cardiomyopathy
    Hussain, Bilal
    Dhulipala, Vishal
    Devarakonda, Pradeep
    Moreno, Pedro
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (04) : S111 - S112
  • [33] Influence of Gender on Clinical Characteristics and Outcomes in Chinese Patients With Hypertrophic Cardiomyopathy
    Huang, Fang-Yang
    Shah, Jageshwar Prasad
    Pu, Xiao-Bo
    Hagar, Abdullah
    Chen, Shi-Jian
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2020, 360 (05): : 517 - 524
  • [34] Patient-reported outcomes in clinical studies of patients with hypertrophic cardiomyopathy
    Reza, Nosheen
    Day, Sharlene M.
    Owens, Anjali Tiku
    PROGRESS IN CARDIOVASCULAR DISEASES, 2023, 80 : 60 - 65
  • [35] Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand
    Nattakorn Songsirisuk
    Veraprapas Kittipibul
    Nilubon Methachittiphan
    Vorawan Charoenattasil
    Nath Zungsontiporn
    Ittikorn Spanuchart
    Saranya Buppajarntham
    Charoen Mankongpaisarnrung
    Sudarat Satitthummanid
    Suphot Srimahachota
    Pairoj Chattranukulchai
    Smonporn Boonyaratavej Songmuang
    Sarinya Puwanant
    BMC Cardiovascular Disorders, 19
  • [36] Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand
    Songsirisuk, Nattakorn
    Kittipibul, Veraprapas
    Methachittiphan, Nilubon
    Charoenattasil, Vorawan
    Zungsontiporn, Nath
    Spanuchart, Ittikorn
    Buppajarntham, Saranya
    Mankongpaisarnrung, Charoen
    Satitthummanid, Sudarat
    Srimahachota, Suphot
    Chattranukulchai, Pairoj
    Songmuang, Smonporn Boonyaratavej
    Puwanant, Sarinya
    BMC CARDIOVASCULAR DISORDERS, 2019, 19 (1)
  • [37] Distinct Phenotypic Groups and Related Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
    Kwak, Soongu
    Kim, Jihoon
    Park, Chan-Soon
    Lee, Hyun-Jung
    Park, Jun-Bean
    Lee, Seung-Pyo
    Kim, Yong-Jin
    Kim, Hyung-Kwan
    Lee, Sang-Chol
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (20):
  • [38] Implications of Atrial Fibrillation on Clinical Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy
    Shafi, Irfan
    Awadelkarim, Abdalaziz
    Alhusain, Rashid
    Minhas, Hersimren
    Lakkis, Nasser
    CIRCULATION, 2022, 146
  • [39] Patient-Reported Outcomes in Clinical Studies of Patients With Hypertrophic Cardiomyopathy
    Reza, Nosheen
    Day, Sharlene
    Owens, Anjali T.
    CIRCULATION, 2022, 146
  • [40] RISK STRATIFICATION AND OUTCOMES OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
    Zilberszac, Robert
    Schukro, Christoph
    Gabriel, Harald
    Maurer, Gerald
    Rosenhek, Raphael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A985 - A985